Proliferation of qui tam suits?
This article was originally published in The Gray Sheet
The Department of Justice currently has over 100 qui tam cases in its docket alleging fraud and abuse by medical device firms, OIG Chief Counsel Lewis Morris said at the recent Pharma, Biotech and Device Colloquium in Princeton, N.J. He predicted that "in the next year or two, as [DoJ] starts to roll out some of these device cases, sales people will start reflecting perhaps on the bogus research and compensation arrangements they have struck with certain doctors...to lock in purchases of certain devices. Once the genie is out of the bottle and they start reporting these instant millionaires, the device industry is going to see more and more qui tams." DoJ issued a subpoena to five major orthopedic device manufacturers in April requesting certain contracts and remuneration agreements between the firms and physicians using their products (1"The Gray Sheet" April 4, 2005, p. 3)...
You may also be interested in...
Several subpoenas of orthopedic manufacturers by the U.S. attorney's office in Newark, N.J. appear to be aimed at alleviating pricing pressure on hospitals for orthopedic devices
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.